Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
crispr-cas9
4
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
4
×
biotech
editas medicine
national
boulder/denver blog main
boulder/denver top stories
cancer
crispr
crispr therapeutics
detroit blog main
detroit top stories
eli lilly
fda
gene editing
glaxosmithkline
intellia therapeutics
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
vertex pharmaceuticals
wisconsin blog main
wisconsin top stories
a2 biotherapeutics
aduro biotech
advaxis
What
crispr
4
×
cas
medicine
bio
editas
editing
gene
roundup
scientists
alliance
beam
big
bosley's
bosley’s
bridge
bristol
bucks
buy
calls
cancer
cells
ceo
changing
color
crime
days
defect
departure
drive
edited
editor
exit
fears
flag
founders
genetic
gotten
growing
guardian
guiding
Language
unset
Current search:
crispr
×
crispr-cas9
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M